Correction: Corrigendum: Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer

Jae Myoung Suh, Johan W. Jonker, Maryam Ahmadian, Regina Goetz, Denise Lackey, Olivia Osborn, Zhifeng Huang, Weilin Liu, Eiji Yoshihara, Theo H. van Dijk, Rick Havinga, Weiwei Fan, Yun-Qiang Yin, Ruth T. Yu, Christopher Liddle, Annette R. Atkins, Jerrold M. Olefsky, Moosa Mohammadi, Michael Downes and Ronald M. Evans

Nature, 2015, vol. 520, issue 7547, 388-388

Abstract: Nature 513, 436–439 (2014); doi:10.1038/nature13540 This Letter should have declared the following competing financial interests: “The fibroblast growth factor (FGF) molecules and related methods of use reported in this study are covered in the following published patent applications and counterparts that derive priority: (1) PCT/US2011/032848, held by R.

Date: 2015
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/nature14304 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:520:y:2015:i:7547:d:10.1038_nature14304

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature14304

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().